The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

被引：0
|
作者：
Zeidan, Amer [1 ,2 ]
Esteve, Jordi [3 ]
Kim, Hee-Je [4 ]
Miyazaki, Yasushi [5 ]
Platzbecker, Uwe [6 ]
Schuh, Andre [7 ]
Westermann, Joerg [8 ]
Malek, Kamel [9 ]
Scott, Jeffrey [10 ]
Niolat, Julie [11 ]
Peyrard, Severine [11 ]
Kiertsman, Flavia [10 ]
Stegert, Mario [9 ]
Fenaux, Pierre [12 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Catholic Univ Korea, Catholic Hematol Hosp, Coll Med, Seoul, South Korea
[5] Nagasaki Univ, Nagasaki, Japan
[6] Univ Hosp Leipzig, Leipzig, Germany
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Charite Univ Med Ctr Berlin, Campus Virchow Clin, Berlin, Germany
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma SAS, Rueil Malmaison, France
[12] Hop St Louis, Paris, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
acute myeloid leukemia; clinical trial; immunotherapy; myelodysplasia; AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-187
引用
收藏
页码：S188 / S188
页数：1
相关论文
共 50 条
  • [31] Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA)
    Braun, T.
    Raffoux, E.
    Prebet, T.
    Stamatoullas, A.
    Brechignac, S.
    Dreyfus, F.
    Samey, B.
    Ades, L.
    Vey, N.
    Dombret, H.
    Fenaux, P.
    Gardin, C.
    LEUKEMIA RESEARCH, 2013, 37 : S149 - S149
  • [32] Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
    Daver, Naval
    Stein, Anthony Selwyn
    Bixby, Dale
    Chai-Ho, Wanxing
    Zeidner, Joshua F.
    Maher, Keri
    Stevens, Don A.
    Stahl, Maximilian
    Yee, Karen
    Curran, Emily K.
    Ito, Sawa
    Sochacki, Andrew
    Sallman, David A.
    Hernandez, Robert
    Metenou, Simon
    Ma, Bo
    Kato, Kazunobu
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [33] Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
    Qi, Junyuan
    Wei, Xudong
    Li, Qiubai
    Chang, Chukang
    Zhou, Fuling
    Huang, Jianying
    Zhang, Yu
    Xu, Chongyuan
    Tang, Xiaowen
    Jiang, Qian
    Li, Junmin
    Qin, Qun
    He, Qun
    Gao, Sujun
    Liu, Liping
    Chen, Zi
    Yu, Min
    Wang, Jing
    Men, Lichuang
    Wang, Hengbang
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [34] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [35] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    BLOOD, 2019, 134
  • [36] Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)
    Yanada, M.
    Huang, X.
    O'Brien, S.
    Garcia-Manero, G.
    Ravandi, F.
    Borthakur, G.
    Issa, J.
    Giles, F.
    Kantarjian, H.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H. -C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 486 - 486
  • [38] ECONOMIC IMPACT OF TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML) AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HIGHER-RISK MDS) IN THE UNITED STATES: RETROSPECTIVE MATCHED COHORT STUDY
    Kota, V.
    Ogbonnaya, A.
    Farrelly, E.
    Schroader, B. Kanz
    Kristo, F.
    Raju, A.
    Dalal, M.
    LEUKEMIA RESEARCH, 2021, 108 : S26 - S27
  • [39] Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents
    Brunner, Andrew M.
    Traer, Elie
    Vey, Norbert
    Scholl, Sebastian
    Tovar, Natalia
    Tovar, Natalia
    Porkka, Kimmo
    Narayan, Rupa
    Garcia-Manero, Guillermo
    Knapper, Steve
    Wermke, Martin
    Janssen, Jeroen J.
    Esteve, Jordi
    Loo, Sun
    Kontro, Mika
    Defilipp, Zachariah
    Wei, Andrew H.
    Borate, Uma
    BLOOD, 2021, 138 : 3677 - +
  • [40] Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation
    Cabrera, Cristina Calderon
    Falantes, Jose F.
    Gomez, Marina
    Parody, Rocio
    Malaver, Francisco J. Marquez
    Martino, Marla L.
    Gonzalez, Jose
    Montero, Isabel
    Espigado, Ildefonso
    Perez-Simon, Jose Antonio
    BLOOD, 2013, 122 (21)
12345